Indaptus Therapeutics (INDP) Accounts Payables (2020 - 2026)
Indaptus Therapeutics (INDP) posted quarterly Accounts Payables of $557367.0 for Q1 2026, down 57.49% year-over-year from $1.3 million in Q1 2025, and up 2.45% quarter-over-quarter from $544057.0 in Q4 2025.
Indaptus Therapeutics (INDP) Accounts Payables (2020 - 2026) Analysis & Trends
Indaptus Therapeutics' Accounts Payables history runs 7 years deep, the most recent figure standing at $557367.0 for Q1 2026.
- In Q1 2026, Accounts Payables fell 57.49% year-over-year to $557367.0; the TTM figure through Mar 2026 stood at $557367.0 (down 57.49% YoY), while the FY2025 annual figure was $544057.0, down 37.48% from the prior year.
- Accounts Payables for Q1 2026 stood at $557367.0, up from $544057.0 in the prior quarter.
- The five-year high for Accounts Payables was $2.8 million in Q1 2022, with the low at $382099.0 in Q1 2023.
- The 5-year median for Accounts Payables is $707420.0 (2025), against an average of $966568.8.
- The sharpest annual moves came in 2022 and 2023: Accounts Payables soared 1449.01% in 2022, then slumped 86.52% in 2023.
- Indaptus Therapeutics' Accounts Payables stood at $1.4 million in 2022, then slumped by 41.52% to $806004.0 in 2023, then increased by 7.97% to $870229.0 in 2024, then tumbled by 37.48% to $544057.0 in 2025, then grew by 2.45% to $557367.0 in 2026.
- Business Quant data shows INDP's Accounts Payables at $557367.0 in Q1 2026, $544057.0 in Q4 2025, and $707420.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Indaptus Therapeutics | 146.91 Mn | 135.35 Mn | - | 508,877.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 508,877.00 |
| Mar 31, 2026 | 557,367.00 |
| Dec 31, 2025 | 544,057.00 |
| Sep 30, 2025 | 707,420.00 |
| Jun 30, 2025 | 618,515.00 |
| Mar 31, 2025 | 1.31 Mn |
| Dec 31, 2024 | 870,229.00 |
| Sep 30, 2024 | 555,949.00 |
| Jun 30, 2024 | 416,555.00 |
| Mar 31, 2024 | 405,457.00 |
| Dec 31, 2023 | 806,004.00 |
| Sep 30, 2023 | 617,270.00 |
| Jun 30, 2023 | 747,674.00 |
| Mar 31, 2023 | 382,099.00 |
| Dec 31, 2022 | 1.38 Mn |
| Sep 30, 2022 | 1.25 Mn |
| Jun 30, 2022 | 2.43 Mn |
| Mar 31, 2022 | 2.83 Mn |
| Dec 31, 2021 | 2.54 Mn |
| Sep 30, 2021 | 3.34 Mn |